A Multicenter, Single Arm, Open-label Study to Investigate the Efficacy and Safety of ABBV-323 in Subjects With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy
Phase of Trial: Phase II
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs Ravagalimab (Primary) ; Ravagalimab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors AbbVie
- 25 Jul 2019 Planned number of patients changed from 40 to 60.
- 05 Jun 2019 Planned number of patients changed from 68 to 40.
- 29 Mar 2019 Planned End Date changed from 23 Mar 2022 to 16 May 2022.